Target family: Voltage-gated potassium channels (K<sub>v</sub>) (type: vgic)
Target: K<SUB>v</SUB>3.1

Ligand: capsaicin (Natural product)
Interaction type: Channel blocker
Action: None
Ligand approved: yes
Approval source: EMA & FDA (2009)
Median affinity: 3.8 pIC50
Reference (Journal): Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines.
Published in: Mol Pharmacol

Ligand: cromakalim (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Median affinity: 3.6 pIC50
Reference (Journal): Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines.
Published in: Mol Pharmacol

Ligand: diltiazem (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: yes
Approval source: FDA (1982)
Median affinity: 4 pIC50
Reference (Journal): Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines.
Published in: Mol Pharmacol

Ligand: fampridine (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: yes
Approval source: FDA (2010), EMA (2011)
Primary target: no
Median affinity: 4.5 pIC50
Reference (Journal): Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines.
Published in: Mol Pharmacol

Ligand: flecainide (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: yes
Approval source: FDA (1985)
Median affinity: 4 pIC50
Reference (Journal): Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines.
Published in: Mol Pharmacol

Ligand: fluoxetine (Synthetic organic)
Interaction type: Gating inhibitor
Action: None
Ligand approved: yes
Approval source: FDA (1987)
Median affinity: 6.1 pIC50
Reference (Journal): Effects of norfluoxetine, the major metabolite of fluoxetine, on the cloned neuronal potassium channel Kv3.1.
Published in: Neuropharmacology

Ligand: nifedipine (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: yes
Approval source: FDA (1981)
Median affinity: 3.9 pIC50
Reference (Journal): Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines.
Published in: Mol Pharmacol

Ligand: norfluoxetine (Synthetic organic)
Interaction type: Gating inhibitor
Action: None
Ligand approved: no
Median affinity: 4.9 pIC50
Reference (Journal): Effects of norfluoxetine, the major metabolite of fluoxetine, on the cloned neuronal potassium channel Kv3.1.
Published in: Neuropharmacology

Ligand: resiniferatoxin (Natural product)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Median affinity: 4.3 pIC50
Reference (Journal): Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines.
Published in: Mol Pharmacol

Ligand: tetraethylammonium (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity: 3.700000047683716 pIC50
Reference (Journal): Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines.
Published in: Mol Pharmacol